Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing

Sukumar Nagendran, Director, President and Head of Research and Development, on July 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $1,248,000. Following the Form 4 filing with the SEC, Nagendran has control over a total of 936,410 common shares of the company, with 936,410 shares held directly. SEC Filing